Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Melinda Cook, Grashma Vadakkel, Stephanie Chinapen, Miguel-Angel Perales, Roni Tamari, Esperanza B. Papadopoulos, Doris M. Ponce, Brian C. Shaffer, Andrew Lin

Blood (2024) 144 (Supplement 1): 7356.

https://doi.org/10.1182/blood-2024-200361

Published: 2024

Journal Articles

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

Warren B Fingrut, Eric Davis, Anne Archer, Samantha Brown, Sean M. Devlin, Melissa Nhaissi, Candice Rapoport, Stephanie Chinapen, Amanda Kelly, Deborah Wells, Andromachi Scaradavou, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Ioannis Politikos, Brian C. Shaffer, Juliet N Barker

Blood (2023) 142 (Supplement 1): 5114.

https://doi.org/10.1182/blood-2023-180439

Published: 2023

Journal Articles

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

Eric Davis, Elise Feuer, Candice Rapoport, Stephanie Lobaugh, Sean M. Devlin, Anne Archer, Stephanie Chinapen, Jacob Federman, Amanda Kelly, Elizabeth Klein, Melissa Nhaissi, Deborah Wells, Juliet N Barker, Esperanza B. Papadopoulos, Andromachi Scaradavou, Jaap Jan Boelens, Miguel-Angel Perales, Elena Maryamchik, Roni Tamari

Blood (2023) 142 (Supplement 1): 113.

https://doi.org/10.1182/blood-2023-190940

Published: 2023

Journal Articles

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Ioannis Politikos, Warren B Fingrut, Samantha Brown, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Miguel-Angel Perales, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2023-190836

Published: 2023

Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Blood (2023) 142 (Supplement 1): 973.

https://doi.org/10.1182/blood-2023-177929

Published: 2023

Journal Articles

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Jelena Ostojić, Rizi Ai, Tara Maier, Mario Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew Harris, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 777.

https://doi.org/10.1182/blood-2023-182198

Published: 2023

Journal Articles

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Ioannis Politikos, Sean M. Devlin, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2023-190528

Published: 2023

Journal Articles

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Toshihisa Satta, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Pamela Susman, Amandeep Singh, Marco Calafiore, Sergio A. Giralt, Miguel-Angel Perales, Jianmin Chen, Simon Li, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2023-181269

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Blood (2022) 140 (Supplement 1): 4759–4761.

https://doi.org/10.1182/blood-2022-159303

Published: 2022

Journal Articles

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

Warren Fingrut, Ioannis Politikos, Eric Davis, Stephanie Chinapen, Kristine Naputo, Christina Cho, Sergio A Giralt, Boglarka Gyurkocza, Ann A Jakubowski, Esperanza B Papadopoulos, Miguel-Angel Perales, Doris M Ponce, Andromachi Scaradavou, Brian C Shaffer, Juliet N Barker

Blood (2021) 138 (Supplement 1): 423.

https://doi.org/10.1182/blood-2021-147329

Published: 2021

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136341

Published: 2020

Journal Articles

Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults

Richard J Lin, MD PhD, Theresa A Elko, MS, Patrick Hilden, MS, Parastoo B. Dahi, MD, Ann A. Jakubowski, MD PhD, Miguel-Angel Perales, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Brian C. Shaffer, MD, Armin Shahrokni, MD, Roni Tamari, MD, Esperanza B. Papadopoulos, MD, Craig S. Sauter, MD, Molly Maloy, MS, Beatriz Korc-Grodzicki, MD PhD, Sergio Giralt, MD

Blood (2018) 132 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2018-99-113876

Published: 2018

Journal Articles

A High Degree of Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies

Blood (2018) 132 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2018-99-116477

Published: 2018

Journal Articles

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Blood (2018) 132 (Supplement 1): 292.

https://doi.org/10.1182/blood-2018-99-112938

Published: 2018

Journal Articles

Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant

Susan Prockop, MD, Stephanie Suser, Ekaterina Doubrovina, MD PhD, Hugo R. Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, Craig S. Sauter, MD, James W. Young, MD, Victoria Szenes, PNP, Alison Slocum, MA, Karim Baroudy, MS, Richard J. O'Reilly, MD

Blood (2018) 132 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2018-99-120133

Published: 2018

Journal Articles

CD34+Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis

Jeong-Ok Lee, MD, Jessica Flynn, BS, Molly Maloy, MS, Ann A. Jakubowski, MD PhD, Esperanza B. Papadopoulos, MD, Christina Cho, MD, Doris Ponce, MD, Craig S. Sauter, MD, Miguel-Angel Perales, MD, Sean M Devlin, PhD, Sergio Giralt, MD, Hugo R. Castro-Malaspina, MD, Roni Tamari, MD

Blood (2018) 132 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2018-99-113166

Published: 2018

NARROW

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

TNC/Kg and CD34+/Kg Cell Dose Impact on Patient Engraftment after Allogeneic Transplant with Conventional Bone Marrow; Better Predictability of Graft Content Needed

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults

A High Degree of Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant

CD34+Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only